Furthermore, although an increased PBM score was associated with the progression and malignant transformation of MM, we are not able to compare the performance of the PBM score with other known risk factors of progression, such as the FLC ratio, plasma cell percentage in the bone marrow, and serum M-protein level, due to data availability. Here, MYOM2 is linked to Miyoshi myopathy.